Combination of CTLA4 and PD-1 blockade with anti-PD-1:B7-H1 monoclonal antibodies increases effector T-cell infiltration into B16 melanoma in mice, resulting in an elevated effector to Treg cell ratio within the tumor [70]. Here, CTLA4 is linked to melanoma.